TI
MTNB icon

Telemetry Investments’s Matinas BioPharma MTNB Stock Holding History

Telemetry Investments’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,631
Closed -$272K – 48
2019
Q3 		$272K Sell
8,631
-2,861
-25% -$103K 0.78% 36
2019
Q2 		$492K Sell
11,492
-1,508
-12% -$72.5K 0.38% 45
2019
Q1 		$708K Buy
+13,000
New +$700K 0.36% 39

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Telemetry Investments's MTNB Position: Q4 2019 in Review

Telemetry Investments sold out of Matinas BioPharma (MTNB) in Q4 2019, closing a stake of 8,631 shares — an estimated $272K sold.

Telemetry Investments first reported a position in MTNB in Q1 2019 and held it in 3 quarters. The position peaked at $708K in Q1 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2019.

  • Telemetry Investments reported no remaining Matinas BioPharma position as of Q4 2019 after selling out during the quarter.
  • Telemetry Investments sold 8,631 Matinas BioPharma shares in Q4 2019, an estimated $272K.
  • Telemetry Investments first reported a position in Matinas BioPharma in Q1 2019 and held it in 3 quarters.
  • Telemetry Investments's Matinas BioPharma position peaked at $708K in Q1 2019.
  • 64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2019.

Based on Telemetry Investments's 13F filing for Q4 2019, filed 14 Feb 2020.